This work describes the development and the application of a lateral flow biosensor for the detection of the prostate specific antigen in urine (uPSA). The biosensor allowed uPSA detection in 10 minutes with a limit of detection and a range of quantification respectively of 20 ng/mL and 37 – 420 ng/mL, showing within and between-day coefficients of variation ≤ 13%. It showed 92% of accuracy and an almost perfect concordance with the reference electrochemiluminescence immunoassay method. The biosensor design provides the disappearance of the Test line signal at the cut-off concentration. This was achieved with a double layer sensing strategy, in which gold nanoparticles were functionalized with Staphylococcal protein A – a mediator – instead of anti-PSA antibody. This strategy allow making a fine-tune on the concentration of the specific antibody, obtaining an on/off switch of the Test line at the cut-off value. The cut-off value was also established in this work, based on the distribution of uPSA levels from 140 patients, who were suspected of prostate cancer and who underwent to first biopsy. The clinical application of the biosensor to predict repeat biopsy outcome in 28 patients showed sensitivity, specificity, positive and negative predictive values of 100%, 64%, 74% and 100%, respectively

Detection of urinary prostate specific antigen by a lateral flow biosensor predicting repeat prostate biopsy outcome

Di Nardo, Fabio;Occhipinti, Sergio;Gontero, Paolo;Cavalera, Simone;Chiarello, Matteo;Baggiani, Claudio;Anfossi, Laura
2020

Abstract

This work describes the development and the application of a lateral flow biosensor for the detection of the prostate specific antigen in urine (uPSA). The biosensor allowed uPSA detection in 10 minutes with a limit of detection and a range of quantification respectively of 20 ng/mL and 37 – 420 ng/mL, showing within and between-day coefficients of variation ≤ 13%. It showed 92% of accuracy and an almost perfect concordance with the reference electrochemiluminescence immunoassay method. The biosensor design provides the disappearance of the Test line signal at the cut-off concentration. This was achieved with a double layer sensing strategy, in which gold nanoparticles were functionalized with Staphylococcal protein A – a mediator – instead of anti-PSA antibody. This strategy allow making a fine-tune on the concentration of the specific antibody, obtaining an on/off switch of the Test line at the cut-off value. The cut-off value was also established in this work, based on the distribution of uPSA levels from 140 patients, who were suspected of prostate cancer and who underwent to first biopsy. The clinical application of the biosensor to predict repeat biopsy outcome in 28 patients showed sensitivity, specificity, positive and negative predictive values of 100%, 64%, 74% and 100%, respectively
325
128812
128820
Di Nardo, Fabio; Occhipinti, Sergio; Gontero, Paolo; Cavalera, Simone; Chiarello, Matteo; Baggiani, Claudio; Anfossi, Laura
File in questo prodotto:
File Dimensione Formato  
saB20_325_128812.pdf

Accesso riservato

Descrizione: versione editoriale
Tipo di file: PDF EDITORIALE
Dimensione 3.08 MB
Formato Adobe PDF
3.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
saB20_325_128812_draft.pdf

Accesso aperto

Descrizione: preprint
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 2.83 MB
Formato Adobe PDF
2.83 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1755115
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact